| Literature DB >> 28062513 |
Cara L Haymaker1, DaeWon Kim1, Marc Uemura1, Luis M Vence2, Ann Phillip1, Natalie McQuail1, Paul D Brown3, Irina Fernandez2, Courtney W Hudgens4, Caitlin Creasy1, Wen-Jen Hwu1, Padmanee Sharma2, Michael T Tetzlaff4,5, James P Allison2, Patrick Hwu1, Chantale Bernatchez6, Adi Diab6.
Abstract
We report here on a patient with metastatic melanoma who had extensive brain metastases. After being treated with the sequential combination of whole brain radiation therapy followed by the PD-1-inhibitory antibody, pembrolizumab, the patient had a durable complete response. Retrospective laboratory studies of T cells revealed that, after treatment with anti-PD-1 commenced, effector CD8+ T cells in the blood expanded and the ratio of CD8+:Treg T cells increased. A CD8+ T-cell clone present in the initial brain metastases was expanded in the blood after anti-PD-1 treatment, which suggested an antitumor role for this clone. Immunohistochemical analysis confirmed the presence of CD8+ T cells and low PD-L1 expression in the brain metastases before immunotherapy initiation. This sequence of therapy may provide an option for melanoma patients with unresponsive brain metastases. Cancer Immunol Res; 5(2); 100-5. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28062513 PMCID: PMC7055516 DOI: 10.1158/2326-6066.CIR-16-0223
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151